- Daily News for Senior Citizens

  FRONT PAGE • Aging • Health • Alzheimer's - Mental • Nutrition • Medicare & Medicaid • Politics  • Fitness  • Social Security • Alerts • Sex Health • Features • Retirement • Elder Care  >Search  >Senior Links


Senior Journal: Today's News and Information for Senior Citizens & Baby Boomers

More Senior Citizen News and Information Than Any Other Source -

• Go to more on Features for Senior Citizens or More Senior News on the Front Page

Follow on  and 

E-mail this page to a friend!

Features for Senior Citizens

New Drug Treatment May Help Elderly with Wet AMD Keep Driving Longer

Small, limited Hopkins study used ranibizumab but did not directly assess driving safety or skills

Oct. 2, 2012 - Results of a new study indicate that monthly injections of ranibizumab (Lucentis) can improve eye chart test results required for a driver's license, build driver confidence and keep the elderly with the wet form of age-related macular degeneration (AMD) driving longer.

The advanced neovascular, or "wet," form of AMD, left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges, according to the study from Johns Hopkins Medicine published in the online version of the journal Ophthalmology.

The wet form of AMD is marked by the abnormal scarring and leaking of new blood vessels in the macula, or center of the retina, the light-sensitive layer of the eye used for driving, reading or recognizing faces.


Related Stories


Safe Driving Prescription for 8 of 10 Seniors Taking Medications Offered by AAA

Roadwise Rx is an online tool that details common side effects of prescription and over-the-counter medications - Sept. 13, 2012

Oldest and Youngest Drivers are Most Dangerous on Road: Consumer Reports

Best cars for the elderly and teenagers recommended by magazine - Aug. 28. 2012

Decision for Senior Citizen to Stop Driving Impacts Mental State, Well-Being

‘Aging is a process where so many things are lost. Part of what seniors try to hold onto is their independence.’ - May 1, 2012

AAA Urges Families to Prepare for the 'Silver Tsunami' of Aging Drivers

Older Driver Safety Awareness Week is Dec. 5-9, AAA emphasizes the importance of communication to help keep senior drivers safe and mobile - AARP Webinar Today

Dec. 5, 2011

More links about seniors driving below news story...

Read more Features for Senior Citizens


Treatment with ranibizumab, a drug made partly from a human monoclonal antibody fragment, is done by injecting it monthly (or as needed with frequent evaluations) into the middle of the eye with a tiny needle about the diameter of a hair. The medicine eliminates or slows new scar and leaking blood vessel formation.

"Driving is an important measure of independence and quality of life for many people in the United States. Participants with wet AMD in our study perceived that they were not driving because of their diminished eyesight," said senior author, Neil M. Bressler, M.D., the James P. Gills Professor of Ophthalmology and chief of the Retina Division at the Wilmer Eye Institute at Johns Hopkins Medicine.

"Our study, believed to be the first of its kind to look at whether outcomes relevant to driving improve with treatment, suggests that monthly injections of ranibizumab may be an extremely helpful option in allowing the elderly to continue driving."

During the phase III, multicentered, randomized two-year clinical trial, researchers used a 25-item National Eye Institute Visual Function Questionnaire to measure study participants' driving ability, perception and self-reported driving status in two distinct studies.

Investigators also conducted monthly assessments, over a two-year period, of the best corrected vision in each eye of 1,126 patients enrolled in these studies that evaluated treatments for AMD. One study compared results for those receiving ranibizumab versus sham (fake) injections; the second compared results of ranibizumab injections versus photodynamic (laser) therapy (PDT) that can seal abnormally leaking blood vessels.

Based on the results of two previous reports from these studies, ranibizumab was better than sham and PDT treatments with respect to avoiding loss of vision when treating patients with an eye affected by wet AMD. This new analysis of those trials by Bressler and colleagues looked beyond the results of these treatments on reading an eye chart to clinically relevant outcomes regarding the impact of this treatment on driving in three ways:

   ● treatment versus no treatment in those who said they were driving or not driving at the beginning and end of the study;

   ● treatment versus no treatment in participants who had vision at the beginning and end of the study that would qualify them for an unrestricted driver's license in at least 45 of the U.S. states; and,

   ● a standardized questionnaire assessing the patients' own perception about the level of difficulty driving in difficult conditions such as rain or fog or at night.

The 45 states all require correctable vision of at least 20/40 in one eye to qualify for an unrestricted driver's license.

"What the study showed was that 85 percent of participants in the ranibizumab versus sham study and 88 percent in the ranibizumab versus PDT study read the eye chart better also achieved the level of vision required for an unrestricted license and in turn had greater confidence in driving," noted Bressler.

The researchers cautioned that more research is needed to determine whether driving skills or driving safety are actually maintained or improved, and whether they match up with patient perceptions of their abilities reported on the questionnaire.

About Ranibizumab Injection (ra'' ni biz' oo mab) – Brand name: Lucentis

Why is this medication prescribed?

Ranibizumab is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Ranibizumab is in a class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss in people with wet AMD.

How should this medicine be used?

Ranibizumab comes as a solution (liquid) to be injected into the eye by a doctor. It is usually given in a doctor's office every month. Your doctor may give you injections on a different schedule if that is best for you.

Before you receive a ranibizumab injection, your doctor will clean your eye to prevent infection and numb your eye to reduce discomfort during the injection. You may feel pressure in your eye when the medication is injected. After your injection, your doctor will need to examine your eyes before you leave the office.

Ranibizumab controls wet AMD, but does not cure it. Your doctor will watch you carefully to see how well ranibizumab works for you. Talk to your doctor about how long you should continue treatment with ranibizumab.

>> More at the National Library of Medicine

"Our study has limitations because these two studies were not designed to directly assess the impact of ranibizumab on driving, and because there was just a small number of patients in the groups that were analyzed relative to the hundreds of thousands of patients affected by the wet form of AMD each year around the world," Bressler stated.

"One of our next steps is to look at these same outcomes when treatment is given for diabetic macular edema, swelling at the center of the retina as a result of diabetes, the most common cause of vision impairment in working-age adults in the U.S. and abroad."

Other researchers in the study included Genentech consultants Tom S. Chang, M.D., from the Retina Institute of California; Rohit Varma, M.D., M.P.H., Doheny Eye Center; Ivan J. Suρer, M.D., Retina Associates of Florida; Paul Lee, M.D., Duke Eye Center, Duke University School of Medicine, Durham, N.C.; Chantal M. Dolan, Ph.D., Genentech, Inc., San Francisco; James Ward, Ph.D., Genentech, Inc., San Francisco; Tsontcho Ianchulev, M.D., Ph.D., affiliated with the University of California, San Francisco and Jennifer T. Fine, Sc.D., Transcend Medical, Menlo Park, Calif.

Notes on Study’s Support

Neil M. Bressler, M.D., receives funding support from Allergan, Bausch & Lomb, Carl Zeiss Meditec, Genentech (which makes ranibizumab and markets it in the United States under the name Lucentis), Notal Vision, Inc., Novartis (which markets ranibizumab outside of the United States), Othera, QLT, Regeneron (which makes aflibercept and markets it in the United States under the name Eylea and competes directly with ranibizumab), and Steba Pharmaceuticals for sponsored projects by the Department of Ophthalmology. Bressler receives salary support for these sponsored projects; the terms of these projects are negotiated and administered by JHU's Office of Research Administration. Under JHU's policy, support for the costs of research, administered by the institution, does not constitute a conflict of interest.

More Links to Archived Reports on Senior Citizens and Driving

Explosion of Older Drivers Pressures Eye Care Professionals to Make Tough Calls

Few eye care providers consider themselves the most-qualified to identify unsafe drivers, few report unsafe drivers

Aug. 23, 2011

Older Baby Boomers Win National Driving Test; Senior Citizens Not Included in Testing

GMAC Insurance study finds about 1 in 5 unfit for road; Kansas drivers most knowledgeable, men best women

June 3, 2011

When Are My Driving Days Over? Author Learns from Helping Her Mother

Noted book author offers tips she learned from helping her mother

March 7, 2011

• Nursing Home Abuse,
• Medical Malpractice -
• Experienced Legal Help

 Beth Janicek, Board Certified Personal Injury Attorney Janicek Law attorneys are working every day to help senior citizens and others harmed by failure of care in nursing homes and the healthcare system.

If you or a loved one have suffered due to the neglect or inadequate care of others, call us today. We offer the skill and knowledge gained in more than twenty years of success.

Free Consultation - Call toll free 1-877-795-3425 or Email


Search for more about this topic on

Google Web

Keep up with the latest news for senior citizens, baby boomers

Click to More Senior News on the Front Page




Published by New Tech Media -

Other New Tech Media sites include,,,, etc.